Table 1:

Demographics of patients with DIBSG included in this study

Patient No.Age (yr)SexTherapiesΔTSurvivalΔTEFSTime of DTI Studies (mo after initial diagnosis)
RTInitial Post-RT Chemotherapy, PrerelapseAt Disease Progression
110.6FRT + CP/ETOIRI + TEM + AVANone12.66.8Bsl, 2.7, 5.9, 8.9,10.7
23.8MRT + CP/ETOIRI + TEM + AVANone10.96.5Bsl, 1.9, 5.1
39MRT + CPNoneNone9.14.2Bsl, 3.3, 5.9
4a8.9MRT + CP/ETOIRI + TEM + AVAAVA, Oral ETO15.48.3Bsl, 2.5, 9.8, 11.1, 13.3, 15.3
58.1FRT + CP/ETOIRI + TEM + AVANone11.25.2Bsl, 2.6, 6.9
64.6FRT + CP/ETOIRI + TEM + AVAAVA, Oral ETO19.112.6Bsl, 8.4, 14.2, 16.2
77.4FRT + TEM/IRITEM/IRINone12.49.6Bsl, 2.7, 6.8
89.5MRT onlyNoneNone6.44.3Bsl, 2.5, 4.3
97FRT + TEMTEMCyclophosphamide (Cytoxan)8.94.6Bsl, 5.3, 6.3
7.7 ± 2.25 F/4 M11.8 ± 3.86.9 ± 2.833 studies
  • a Biopsy-confirmed anaplastic astrocytoma at presentation, glioblastoma at postmortem examination.